P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)

Bibliographic Details
Main Authors:	Nabel GJ, Mascola JR, Koup RA, Roederer M, Bailer RT, Nason MC, Holman LA, Gordon IJ, Enama ME, Novik L, Ledgerwood JE, Graham BS
Format:	Article
Language:	English
Published:	BMC 2009-10-01
Series:	Retrovirology

Similar Items

Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011).
by: Mary E Enama, et al.
Published: (2014-01-01)

P14-12. Safety and tolerability of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular, subcutaneous and intradermal administration in healthy adults
by: Ledgerwood J, et al.
Published: (2009-10-01)

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).
by: Michelle C Crank, et al.
Published: (2016-01-01)

Partial germline reversions can increase VRC07 potency and breadth
by: Rudicell RS, et al.
Published: (2012-09-01)

FINAD + VRC = Controllers Instituut
by: G. H. Koolman
Published: (1995-05-01)

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
by: Yunda Huang, et al.
Published: (2018-09-01)

Adjuvants influence the maturation of VRC01-like antibodies during immunization
by: Maria L. Knudsen, et al.
Published: (2022-11-01)

Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
by: Lynch RM, et al.
Published: (2012-09-01)

Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
by: Yunda Huang, et al.
Published: (2021-02-01)

Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination
by: Mata-Fink, Jordi, et al.
Published: (2013)

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
by: Kenneth H Mayer, et al.
Published: (2017-11-01)

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
by: Martin R Gaudinski, et al.
Published: (2018-01-01)

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
by: Yunda Huang, et al.
Published: (2022-01-01)

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisitionResearch in context
by: Kelly E. Seaton, et al.
Published: (2023-07-01)

Mendeteksi dan membetulkan kesalahan data digital menggunakan metode VRC dan LRC
by: , RASYID, Rum Mohamad Andri Kristiyanto, et al.
Published: (2001)

Selection of peptide mimics of HIV-1 epitope recognized by neutralizing antibody VRC01.
by: Anton N Chikaev, et al.
Published: (2015-01-01)

Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
by: K. Rachael Parks, et al.
Published: (2019-12-01)

Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features.
by: Craig A Magaret, et al.
Published: (2019-04-01)

Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaques.
by: Giulia Calenda, et al.
Published: (2019-05-01)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
by: Labranche, CC, et al.
Published: (2018)

DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial.
by: Barney S Graham, et al.
Published: (2013-01-01)

Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.
by: Uzma N Sarwar, et al.
Published: (2014-01-01)

A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention
by: Young D. Kwon, et al.
Published: (2021-01-01)

Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
by: Yunda Huang, et al.
Published: (2023-11-01)

Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain
by: Young D. Kwon, et al.
Published: (2023-12-01)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
by: Celia C LaBranche, et al.
Published: (2018-11-01)

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.
by: Nonhlanhla N Mkhize, et al.
Published: (2023-06-01)

Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies
by: Emilie Seydoux, et al.
Published: (2021-05-01)

First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody
by: Denis R. Beckford-Vera, et al.
Published: (2022-03-01)

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
by: Celia C LaBranche, et al.
Published: (2019-03-01)

Best infection control practices for intradermal, subcutaneous, and intramuscular needle injections
by: Hutin Yvan, et al.
Published: (2003-01-01)

Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01
by: E. Fabian Cardozo-Ojeda, et al.
Published: (2021-08-01)

Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection.
by: Ananya Saha, et al.
Published: (2020-11-01)

Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies.
by: Yuka Otsuka, et al.
Published: (2018-08-01)

Variable formation control of multiple robots via VRc and formation switching to accommodate large heading changes by leader robot
by: Sung-Gil Wee, et al.
Published: (2019-06-01)

Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells
by: Jeong Hyun Lee, et al.
Published: (2021-09-01)

V5 region in the HIV-1 envelope glycoprotein determines viral sensitivity to the broadly neutralizing monoclonal antibody VRC01
by: Guo D, et al.
Published: (2012-09-01)

Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition
by: Jason Gorman, et al.
Published: (2020-04-01)

Arrangement of VL and VH Domains in VRC01-Based Chimeric Antigen Receptor (CAR) Affects Functions and Exhaustion Status of CAR-T Cells
by: Jun-Ichi Nunoya, et al.
Published: (2021-01-01)

Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors
by: Christina Yacoob, et al.
Published: (2016-11-01)